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OBJECTIVE— Adiponectin is an adipose tissue–derived protein. Low levels are associated
with obesity, insulin resistance, and type 2 diabetes. Our objective was to investigate the pro-
spective association between adiponectin levels and the 6.4-year risk of type 2 diabetes and of
impaired glucose metabolism (IGM).
RESEARCH DESIGN AND METHODS— The Hoorn Study is a cohort study among
Caucasians, aged 50–75 years. BMI, waist-to-hip ratio (WHR), fasting glucose, 2-h glucose,
triglycerides, HDL cholesterol, LDL cholesterol, alanine aminotransferase, leptin, and adiponec-
tin were measured at baseline. Lifestyle (alcohol intake, smoking, and physical activity) was
assessed by questionnaires. After a mean follow-up of 6.4 years, glucose tolerance was assessed
by a 75-g oral glucose tolerance test. Analyses were performed in 1,264 subjects (584 men and
680 women) without type 2 diabetes at baseline. For analyses of incident IGM, 239 subjects with
IGM at baseline and/or type 2 diabetes at follow-up were excluded.
RESULTS— Age- and lifestyle-adjusted odds ratios and 95% CIs comparing highest with
lowest adiponectin quartile were 0.52 (0.23–1.18) in men and 0.15 (0.06–0.39) in women for
type 2 diabetes and 0.90 (0.51–1.61) and 0.28 (0.16–0.48) for IGM, respectively. The risks were
only slightly reduced after adjustment for WHR and leptin as markers of (abdominal) adiposity.
Adjustment for baseline fasting and postload glucose levels (potential mediators) substantially
diminished these inverse associations with type 2 diabetes (0.79 [0.32–1.91] and 0.62 [0.21–
1.81]) and with IGM (1.20 [0.61–2.35] and 0.48 [0.26–0.90]), respectively.
CONCLUSIONS— A high adiponectin level was strongly associated with a lower risk of
IGM and type 2 diabetes, particularly in women. These results suggest that adiponectin is
involved in the pathophysiology linking obesity to type 2 diabetes.
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The pathophysiology linking obesityto type 2 diabetes is not completelyunderstood, but adipokines are
thought to be involved (1). Adiponectin is
a recently discovered protein that seems
to be exclusively secreted by adipocytes
and is the most abundant adipose tissue–
derived protein (2,3). In contrast to other
adipokines (such as leptin and interleu-
kin-6) that are often elevated in obese
subjects, adiponectin is reduced (3–6).
In animal studies, adiponectin has
been shown to have insulin-sensitizing
properties. Adiponectin knockout mice
are insulin resistant in a gene-dose fash-
ion (7,8). Overexpression of adiponectin
prevented diabetes in transgenic mice (9),
and administration of adiponectin re-
versed insulin resistance in various mouse
models of obesity and diabetes (10). Adi-
ponectin increased insulin action via ef-
fects on hepatic glucose production and
by increasing fat oxidation and lowering
circulating free fatty acids (10–13).
In humans, several cross-sectional
studies showed that adiponectin corre-
lates negatively with measures of insulin
resistance and type 2 diabetes, but cause
or consequence cannot be distinguished.
Results from a few prospective studies
suggest that a low adiponectin level is pre-
dictive of insulin resistance or diabetes in
Pima Indians (14), Asian Indians (15),
and Japanese subjects (16,17). Some of
these studies are rather small (14,15) or
had a short follow-up period (15,17). To
our knowledge, the only prospective
study in Caucasians was a nested case-
control study based on self-reported dia-
betes after a follow-up of 2–3 years (18).
All of these previous prospective studies
were performed in relatively young
subjects.
The objective of the present study was
to investigate the association between adi-
ponectin and subsequent 6.4-year inci-
dence of abnormal glucose metabolism in
a large population-based cohort of older
men and women.
RESEARCH DESIGN AND
METHODS— The Hoorn Study is a
population-based cohort study among
2,484 Caucasians (aged 50–75 years) that
was performed in 1989–1991 and has
been described previously (19). In 1996–
1998, a follow-up examination took
place. Of the 2,484 subjects, 150 subjects
had died and 108 subjects had moved out
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of Hoorn. Another 140 subjects were not
invited because of logistic reasons. Of the
remaining 2,086 subjects, 1,513 (72.5%)
participated. At both examinations, an ex-
tensive physical examination and an oral
glucose tolerance test were performed.
For the present analyses, from the
baseline population (n  2,484) we ex-
cluded subjects with missing baseline
data (n  184) and subjects who already
had type 2 diabetes (either newly detected
or previously diagnosed) at baseline (n
224). From the remaining 2,076 subjects,
1,264 persons had follow-up data avail-
able on glucose tolerance status and were
included for prospective analyses. In-
formed consent was obtained from all
participants, and ethical approval was ob-
tained from the Ethical Review Commit-
tee of the VU University Medical Center.
Adiponectin
Baseline adiponectin was determined in
2004 in spare plasma samples that had
been stored at80°C and had never been
thawed before. Adiponectin was deter-
mined by a latex turbidometric immuno-
assay (Otsuka Pharmaceutical). The inter-
and intra-assay coefficients of variation
were 2.0 and 3.1%, respectively.
Glucose metabolism
Fasting glucose and 2-h postload glucose
levels after a 75-g oral glucose tolerance
test were measured by the glucose dehy-
drogenase method (Merck, Darmstadt,
Germany) at baseline and by the hexoki-
nase method (Boehringer-Mannheim,
Mannheim, Germany) at follow-up. Glu-
cose levels were used to classify subjects
according to the 1999 World Health Or-
ganization criteria into normal glucose
metabolism, impaired glucose metabo-
lism (IGM) (impaired fasting glucose
and/or impaired glucose tolerance), or
type 2 diabetes.
Additional measurements
Serum lipids and lipoproteins were deter-
mined by enzymatic techniques (Boe-
hringer-Mannheim). Serum leptin
concentrations (micrograms per liter)
were determined by a radioimmunoassay.
Serum alanine aminotransferase (ALT)
enzyme activity was measured according
to the method of the International Feder-
ation of Clinical Chemistry of 1985 and
expressed as units per liter (20). The se-
rum creatinine level was determined to
calculate the glomerular filtration rate
(GFR) by the Cockcroft-Gault formula in
milliliters per minute per 1.73 m2 body
surface area. BMI (weight in kilograms di-
vided by the square of height in meters)
and waist-to-hip ratio (WHR) were calcu-
lated. Blood pressure (millimeters of mer-
cury) was measured in duplicate by
means of a random-zero sphygmoma-
nometer (Hawksley-Gelma, Lancing,
U.K.). Information on lifestyle factors was
obtained by questionnaires. Habitual
Table 1—Baseline characteristics of men by quartiles of adiponectin
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend Ptrend*
n 145 151 143 145
Adiponectin (g/ml) 5.66  0.89 7.92  0.65 10.30  0.77 20.41  6.75 0.001 0.001
Age (years) 57.4  5.9 59.7  6.5 60.5  7.2 62.4  7.0 0.001 —
Anthropometry
BMI (kg/m2) 26.6  2.8 26.2  2.4 26.1  3.6 25.1  2.5 0.001 0.001
Waist circumference (cm) 95.6  8.4 94.7  7.5 94.0  9.0 91.9  8.1 0.001 0.001
Hip circumference (cm) 101.1  5.7 100.3  4.7 100.1  5.1 99.3  5.0 0.002 0.003
WHR 0.94  0.05 0.94  0.05 0.93  0.07 0.93  0.06 0.004 0.001
Metabolic variables
Fasting glucose (mmol/l) 5.48  0.50 5.54  0.51 5.41  0.48 5.40  0.50 0.046 0.013
2-h glucose (mmol/l) 5.39  1.63 5.35  1.70 4.83  1.48 5.03  1.51 0.006 0.001
LDL cholesterol (mmol/l) 4.44  0.93 4.52  1.03 4.46  0.93 4.53  0.95 0.583 0.575
HDL cholesterol (mmol/l) 1.16  0.31 1.14  0.25 1.18  0.24 1.33  0.36 0.001 0.001
Triglycerides (mmol/l) 1.4 (1.1–2.2) 1.5 (1.1–2.1) 1.4 (1.0–1.7) 1.2 (1.0–1.7) 0.001 0.001
Systolic blood pressure
(mmHg)
133.8  18.8 132.0  16.7 130.3  16.3 134.2  18.6 0.951 0.025
Diastolic blood pressure
(mmHg)
85.0  9.2 83.1  9.6 81.7  8.7 82.4  10.7 0.011 0.013
Leptin (g/l) 3.29 (1.73–5.59) 3.51 (1.79–5.74) 3.13 (1.95–4.71) 2.43 (1.36–4.94) 0.002 0.001
ALT activity (units/l) 16.6  10.9 14.2  8.3 13.3  6.2 11.9  5.4 0.000 0.000
GFR (ml/min per 1.73 m2) 74.7  12.3 71.1  10.0 70.9  11.7 69.7  12.7 0.001 0.668
Lifestyle factors
Smoking (% yes) 31.7 39.7 40.6 32.4 0.881 0.696
Habitual physical activity
(h/day)
2.8 (1.6–4.4) 2.9 (1.7–5.0) 3.0 (1.9–5.1) 3.1 (2.0–5.0) 0.217 0.878
Sports (% yes) 34.5 29.1 30.1 25.5 0.127 0.865
Alcohol (% yes) 90.3 87.1 84.2 85.8 0.199 0.601
Alcohol (g/day)
0 9.7 12.9 15.8 14.2 0.199 0.601
10 39.6 43.5 43.9 43.3 0.539 0.603
10–30 34.0 32.7 30.9 34.8 0.980 0.662
30 16.7 10.9 9.4 7.8 0.018 0.046
Data are means  SD or median (interquartile range) unless otherwise indicated. *Ptrend adjusted for age.
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physical activity (hours per day) included
sports, bicycling, gardening, walking,
odd jobs, and housekeeping. An addi-
tional variable was created that only in-
cluded performing sports (yes/no).
Statistical analyses
Baseline characteristics are presented for
men and women separately according to
sex-specific quartiles of adiponectin. To
test for trend over the adiponectin quar-
tiles, linear (for continuous dependent
variables) or logistic (for dichotomous de-
pendent variables) regression analyses
were performed, modeling the categorical
variable of adiponectin quartiles as a con-
tinuous independent variable. Variables
with a skewed distribution were log nor-
mal transformed for these analyses.
For prospective analyses, we first
plotted the incidence density of type 2
diabetes (number of cases per person-
years) against mean adiponectin within
each sex-specific quartile of adiponectin.
Logistic regression analyses were then
performed to calculate the risk (odds ra-
tios [ORs] with 95% CIs) of developing
type 2 diabetes or developing IGM during
a mean follow-up of 6.4 years. The lowest
adiponectin quartile was the reference
group. In separate analyses, the continu-
ous adiponectin variable was used as in-
dependent variable. In this case, the OR
was expressed per sex-specific SD of adi-
ponectin. For the analyses on the inci-
dence of IGM, subjects with IGM (n 
189) at baseline and/or with type 2 diabe-
tes at follow-up (n 118) were excluded
(leaving 1,025 subjects for analyses). Ef-
fect modification by sex was examined by
adding an interaction term (adiponectin
quartiles sex) to the regression models.
Because there was significant interaction
by sex (P 0.051 for type 2 diabetes and
P  0.002 for IGM), the analyses were
subsequently performed and reported
separately for men and women. Further
adjustments were made for age, sex, life-
style factors, anthropometric variables,
leptin, baseline fasting and postload glu-
cose, lipids, ALT, and GFR by adding
these variables to the regression models.
All statistical analyses were performed us-
ing SPSS (version 11.0 for Windows;
SPSS, Chicago, IL).
RESULTS— Baseline characteristics
are shown in Table 1 (men) and Table 2
(women). At baseline, after adjustment
for age, a low adiponectin level was
strongly associated with unfavorable
measures of anthropometric body com-
position and measures of glucose (except
for HbA1c in men) and lipid metabolism
(except for LDL cholesterol in men). A
low adiponectin level was also associated
with high leptin levels and with high sys-
tolic and diastolic blood pressure. In
women, smoking was associated with
Table 2—Baseline characteristics of women by quartiles of adiponectin
Quartile 1 Quartile 2 Quartile 3 Quartile 4 Ptrend Ptrend*
n 170 170 170 170
Adiponectin (g/ml) 8.48  1.74 12.67  1.03 16.60  1.26 24.78  5.72 0.001 0.001
Age (years) 59.1  6.4 59.5  6.7 60.2  6.6 62.2  7.2 0.001 —
Anthropometry
BMI (kg/m2) 27.3  3.3 26.8  3.8 26.2  3.3 25.7  3.1 0.001 0.001
Waist circumference (cm) 88.5  9.3 87.2  10.4 85.4  9.5 82.3  9.0 0.001 0.001
Hip circumference (cm) 103.1  6.9 103.6  7.4 102.7  6.4 102.3  6.8 0.185 0.045
WHR 0.86  0.07 0.84  0.07 0.83  0.07 0.80  0.07 0.001 0.001
Metabolic variables
Fasting glucose (mmol/l) 5.46  0.50 5.32  0.48 5.27  0.54 5.13  0.51 0.001 0.001
2 h glucose (mmol/l) 6.18  1.72 5.42  1.38 5.28  1.44 5.07  1.33 0.001 0.001
LDL cholesterol (mmol/l) 4.81  1.19 4.60  1.03 4.67  1.07 4.51  1.00 0.023 0.012
HDL cholesterol (mmol/l) 1.30  0.32 1.46  0.34 1.54  0.32 1.66  0.37 0.001 0.001
Triglycerides (mmol/l) 1.7 (1.2–2.2) 1.3 (1.0–1.7) 1.2 (0.9–1.5) 1.0 (0.8–1.3) 0.001 0.001
Systolic blood pressure
(mmHg)
134.0  20.9 132.2  20.1 132.0  20.5 130.0  19.4 0.082 0.001
Diastolic blood pressure
(mmHg)
81.6  10.0 80.7  9.7 79.9  9.7 78.9  10.7 0.010 0.006
Leptin (g/l) 16.44 (10.14–27.30) 12.13 (7.75–22.78) 14.82 (8.40–25.02) 10.86 (6.43–18.90) 0.001 0.001
ALT activity (units/l) 10.9  4.9 10.4  4.3 11.2  6.6 10.3  4.6 0.582 0.762
GFR (ml/min per 1.73 m2) 73.1  12.4 73.0  12.0 70.6  11.0 69.3  10.6 0.001 0.149
Lifestyle factors
Smoking (% yes) 35.7 27.8 27.1 16.5 0.001 0.001
Habitual physical activity
(h/day)
4.4 (3.3–6.0) 4.7 (3.3–6.3) 4.6 (3.4–5.9) 4.1 (3.0–5.7) 0.210 0.451
Sports (% yes) 28.4 33.5 39.4 38.8 0.024 0.004
Alcohol (% yes) 58.3 64.5 61.8 61.7 0.664 0.232
Alcohol (g/day)
0 41.7 35.5 38.2 38.3 0.674 0.232
10 37.5 43.8 44.1 46.1 0.126 0.079
10–30 18.5 18.3 10.0 14.4 0.097 0.242
30 2.4 2.4 7.6 1.2 0.771 0.506
Data are means  SD or median (interquartile range) unless otherwise indicated. *Ptrend adjusted for age.
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lower adiponectin levels, and participat-
ing in sports was associated with higher
adiponectin levels.
The mean follow-up duration was
6.4  0.5 years for both sexes. Figure 1
shows the crude association between adi-
ponectin levels and the incidence density
of type 2 diabetes. High adiponectin lev-
els were associated with a lower incidence
of type 2 diabetes, and this association
appeared stronger in women than in men.
After adjustment for age and lifestyle,
higher adiponectin levels at baseline were
associated with a lower risk of develop-
ment of type 2 diabetes, although not sta-
tistically significant in men (Table 3,
model 1). Adjustment for leptin, as a
marker for body fat, and WHR weakened
the associations, particularly in women
(model 2). Adjustment for waist and hip
separately or for waist circumference
alone instead of WHR or additional ad-
justment for BMI yielded similar results
(not shown). Adjustment for glucose lev-
els, particularly postload glucose, sub-
stantially weakened the associations
(model 3). Additional adjustment for trig-
lycerides also diminished the associations
(model 4), whereas adjustment for LDL
cholesterol did not (not shown). Adjust-
ment for HDL cholesterol instead of trig-
lycerides diminished the strength of the
associations (ORs [95% CI] in quartile 2,
3, and 4 were 0.66 [0.29–1.52], 0.95
[0.40 –2.25], and 0.75 [0.30 –1.90] in
men and 0.98 [0.44–2.19], 0.75 [0.31–
1.80], and 0.71 [0.23–2.17] in women,
respectively), but not if triglycerides were
already entered into the model (data not
shown). Adjustment for ALT or GFR (in-
stead of triglycerides in model 4) did not
change the associations (not shown). If
only subjects with normal glucose toler-
ance were selected (subjects with IGM at
baseline also excluded) the risk of devel-
opment of diabetes associated with low
adiponectin levels became stronger: the
OR (95% CI) for the highest compared
with the lowest adiponectin quartile was
0.45 (0.14–1.47) in men and 0.17 (0.03–
0.83) in women, after adjustment for age,
lifestyle, and WHR.
The association between adiponectin
levels and the incidence of IGM (Table 4)
had a pattern similar to that for the asso-
ciation with type 2 diabetes in women,
but the association of a high adiponectin
level with a lower risk of IGM was not
observed in men. We also calculated the
risk for the incidence of impaired fasting
glucose and impaired glucose tolerance
separately. After adjustment for age, life-
style, and WHR, the ORs (95% CI) for
highest compared with lowest adiponec-
tin quartile were 1.15 (0.60–2.20) in men
and 0.54 (0.28–1.03) in women for im-
paired fasting glucose and 0.92 (0.34–
2.44) in men and 0.28 (0.12–0.68) in
women for impaired glucose tolerance.
CONCLUSIONS— Our main find-
ing is that a lower adiponectin level is as-
sociated with a higher risk of developing
type 2 diabetes after a mean follow-up of
6.4 years in an elderly Caucasian popula-
tion. This association was largely ex-
plained by fasting and postload glucose
levels. In women with a normal glucose
metabolism at baseline, a low adiponectin
level was associated with an increased risk
of developing IGM (pre-diabetic state),
but this association was not observed in
men. To our knowledge, our study is the
first prospective cohort study in elderly
Caucasian men and women.
Baseline adiponectin independently
predicted subsequent type 2 diabetes
during 6.4 years of follow-up in our pop-
ulation. Together with the observation
that weight reduction affected adiponec-
tin (5), but that adiponectin did not pre-
dict weight change (17), our results
support the hypothesis that adiponectin
may play an important role in the patho-
genesis of abnormal glucose metabolism.
It is suggested that, possibly as a result of
a low adiponectin level, liver fat accumu-
lation plays a key role in the development
of metabolic disturbances (21). However,
ALT, which is used as a marker of liver fat
accumulation, was inversely associated
with adiponectin in men but not in
women. Additional analyses revealed that
an inverse association between ALT and
adiponectin existed in the entire popula-
tion of women, but it disappeared once
Figure 1—Incidence density of type 2 diabetes
within sex-specific adiponectin quartiles, after
a mean follow-up of 6.4 years. , men; Œ,
women.
Table 3—Risk of developing type 2 diabetes in 6.4 years associated with adiponectin
Adiponectin
Continuous, per SDQuartile 1 Quartile 2 Quartile 3 Quartile 4
Men
Cases (%) 12.4 (18/145) 10.6 (16/151) 9.8 (14/143) 8.3 (12/145) 10.3 (60/584)
Model 1 1.0 0.77 (0.37–1.61) 0.67 (0.31–1.46) 0.52 (0.23–1.18) 0.83 (0.62–1.12)
Model 2 1.0 0.79 (0.38–1.67) 0.71 (0.33–1.55) 0.61 (0.27–1.40) 0.89 (0.66–1.20)
Model 3 1.0 0.66 (0.29–1.52) 0.96 (0.41–2.27) 0.79 (0.32–1.91) 1.01 (0.74–1.39)
Model 4 1.0 0.67 (0.29–1.54) 0.98 (0.41–2.33) 0.80 (0.33–1.95) 1.02 (0.75–1.40)
Women
Cases (%) 15.8 (27/170) 8.2 (14/170) 7.2 (11/170) 3.5 (6/170) 8.5 (58/680)
Model 1 1.0 0.48 (0.24–0.97) 0.37 (0.18–0.97) 0.15 (0.06–0.39) 0.42 (0.28–0.62)
Model 2 1.0 0.58 (0.28–1.20) 0.47 (0.22–1.01) 0.27 (0.10–0.73) 0.55 (0.36–0.83)
Model 3 1.0 0.91 (0.41–2.00) 0.68 (0.29–1.61) 0.62 (0.21–1.81) 0.78 (0.52–1.18)
Model 4 1.0 0.97 (0.43–2.17) 0.75 (0.31–1.80) 0.69 (0.23–2.07) 0.82 (0.54–1.26)
Data are OR (95% CI) unless otherwise indicated. Model 1: adjusted for age and lifestyle (smoking and sports). Model 2: model 1 plus adjusted for leptin (log normal
transformed) and WHR. Model 3: model 2 plus adjusted for fasting and postload glucose. Model 4: model 3 plus adjusted for triglycerides (log normal transformed).
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women with type 2 diabetes were ex-
cluded. An association of ALT with inci-
dent type 2 diabetes was previously found
in the Hoorn Study (which also disap-
peared after additional adjustment for
baseline glucose levels); however, a pos-
sible difference between men and women
was not evaluated (22). Our results sug-
gest that the association between adi-
ponectin and incident type 2 diabetes was
not explained by ALT.
Adjustment for glucose (particularly
postload glucose) and triglycerides sub-
stantially reduced the associations be-
tween adiponectin and incident type 2
diabetes. This could suggest that the asso-
ciations are (partly) mediated by these
factors, confirming the hypothesis of adi-
ponectin contributing to type 2 diabetes
risk through effects on (hepatic) insulin
resistance. Previous prospective studies
found associations between adiponectin
and type 2 diabetes, even independent of
fasting glucose levels. It is likely, however,
that this is caused by residual effects of
postload glucose and triglycerides, which
were usually not measured.
There are still unexplained phenom-
ena concerning adiponectin metabolism.
The association between adiponectin and
type 2 diabetes was stronger in women
than in men. Because of differences in de-
sign among studies, it is difficult to com-
pare the absolute strength of the
association, but a sex difference has pre-
viously been shown in younger adults
(18), with stronger associations also being
shown in women. Other prospective
studies on adiponectin and type 2 diabe-
tes did not report on possible differences
between men and women (14–17). It is
remarkable that, despite their higher
body fat percentage, women appear to
have higher adiponectin levels than men.
Previously, this difference could not be
explained by differences in fat distribu-
tion (6). Another counterintuitive obser-
vation is that adiponectin is positively
associated with age. This has also been
shown in many other studies in which the
association between adiponectin and age
was reported (e.g., the study by Cnop et
al. [6] and the Funagata Study [16]) but
so far has received little attention. So, de-
spite the increase in body fat with aging
and the accompanying increased cardio-
vascular risk, adiponectin levels also in-
crease. These observations emphasize
that the mechanisms that underlie the as-
sociation between adiponectin and dis-
turbed glucose metabolism are poorly
understood. Recent work has shown that
adiponectin exists in different isoforms,
low–molecular weight and high–
molecular weight (HMW) complexes (2).
Diabetic patients had a significantly de-
creased HMW-to-total adiponectin ratio
(23), and HMW adiponectin correlated
better with glucose tolerance than total
adiponectin in Indo-Asian males (24).
Also, a relatively larger increase in HMW
adiponectin after weight reduction has
been shown (25). These findings indicate
that the HMW adiponectin complex is
possibly the active form of this protein.
Women have more HMW adiponectin
than men (23), which may partly explain
the differences that we have found be-
tween men and women.
A limitation of the present study may
be that we had no repeated measurement
of adiponectin at the follow-up examina-
tion. Adiponectin levels may have
changed considerably after6 years. De-
spite the long follow-up duration, how-
ever, we were still able to find an
association indicating that the relation is
very strong. In addition, participants in
the follow-up examination were healthier
at baseline than the nonparticipants (26).
This may have led to an underestimation
of the true incidence of type 2 diabetes
and consequently to an underestimation
of the associations with adiponectin.
In summary, our findings strongly
support the hypothesis that adiponectin
may play an important role in the patho-
genesis of abnormal glucose metabolism.
However, further investigation of the un-
derlying mechanisms, focusing on adi-
ponectin isomer distribution, is needed to
elucidate the associations of adiponectin
with sex and age.
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